MannKind Corp - Company Profile
Powered by 
All the sales intelligence you need on MannKind Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MannKind Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MannKind Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MannKind Corp (MannKind) is a biopharmaceutical company primarily engaged in the development and commercialization of inhaled therapeutic products and devices. The company's main focus is on addressing unmet medical needs for patients with endocrine and orphan lung diseases. MannKind's major offerings include dry-powder formulations and inhalation devices, designed to deliver medicines rapidly and conveniently to the deep lung. Its technologies are used in the treatment of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. Mannkind has manufacturing facility in Danbury, Connecticut and sells products to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.
Headquarters
United States of America
Address
1 Casper Street, Danbury, Connecticut, 06810
Website
www.mannkindcorp.com
Telephone
1 818 6615000
No of Employees
591
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MNKD (NASD)
Revenue (2025)
$349.0M
22.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-78.7%
(2025 vs 2024)
Market Cap*
$1.1B
Net Profit Margin (2025)
XYZ
-82.6%
(2025 vs 2024)
* As of and is in US$
MannKind Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Afrezza - Diabetes | Afrezza |
| V-Go - Wearable Insulin Delivery Device | MannKind |
| Technology: | Technosphere |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In October, the company acquired scPharmaceuticals, a pharmaceutical company. |
| 2024 | Regulatory Approval | In May, the company received Fast Track designation from the US Food and Drug Administration (FDA) for Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease. |
| 2024 | Acquisitions/Mergers/Takeovers | In January, the company acquired a 1% royalty in the net sales of Tyvaso DPI (treprostinil) inhalation powder from Sagard Healthcare. |
Competitor Comparison
| Key Parameters | MannKind Corp | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Danbury | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Connecticut | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 591 | 138,200 | 47,000 | 73,000 | 81,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James S. Shannon, M.D | Chairman | Executive Board | 2020 | 69 |
| Michael E. Castagna | Chief Executive Officer; Director | Executive Board | 2017 | 49 |
| Christopher B. Prentiss | Chief Financial Officer | Senior Management | 2024 | 50 |
| Ajay Ahuja, MD | Chief Medical Officer; Executive Vice President | Senior Management | 2025 | 57 |
| Stuart A. Tross, Ph.D. | Chief People and Workplace Officer | Senior Management | 2016 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer